Dr Loveridge has been working in the biomedical technology industry for over 20 years and has extensive experience in developing clinical stage biotechnology companies. As a venture investor with JAFCO Nomura, Dr Loveridge participated and invested in the start-up of over 24 companies in Europe, the United States and Israel. Since 2005, he has been directly involved in senior management of a number of small innovative companies in the biomedical field, specifically in refinancing and product commercialisation.
In addition to Actinogen Medical, Dr Loveridge is also a Non-Executive Director of Resonance Health (ASX: RHT) and CEO of German based biopharmaceutical company 4SC AG.
Dr Loveridge holds a PhD in Biochemistry and is a fellow of the Royal Society of Medicine.